Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Pharmaceutical Technology2h
RFK Jr. trumps domestic manufacturing agenda Day 2 of confirmation hearings
During a Senate HELP Committee hearing, RFK Jr. stated that President Trump is dedicated to bringing drug manufacturing "back ...
Jim Cramer Defends Eli Lilly and Company (LLY) Amid Concerns Over Drug Adherence, Cites Long-Term Health Potential
We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
pharmaphorum23h
Lawmakers seek answers on Pfizer, Lilly telehealth moves
US Senators are concerned that Pfizer and Eli Lilly's recent forays into direct ... which currently covers 15 of its most common medicines, along with diagnostics and treatments for COVID-19 ...
Covers23h
Today's NBA Picks
The Cavaliers defense has been cooked by opposing PGs this season, as the Cavs have allowed the most points per game to the position at 26.6. Over the last seven, Cleveland has surrendered a ...